Bristol Myers Squibb Co (NYSE: BMYMP)

Bristol-Myers Squibb Company (BMS), a prominent player in the biopharmaceutical industry, is a global entity involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. Established in 1887, the company has its headquarters in New York City.

BMS's primary business activities encompass the biopharmaceutical sector, focusing on four main therapeutic areas: oncology, hematology, immunology, and neuroscience. The company's operations span various countries and regions, including the United States, Puerto Rico, Switzerland, Ireland, and the Netherlands, among others.

The company's revenue is primarily generated from the sale of pharmaceutical products. These products are categorized into the aforementioned therapeutic areas and are sold worldwide, mainly to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, directly to retailers, hospitals, clinics, and government agencies. Some of BMS's key products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Abecma, Opdualag, Breyanzi, Camzyos, Sotyktu, Onureg, Inrebic, and Zeposia. These products are used to treat a wide range of diseases and conditions, such as cancer, multiple myeloma, rheumatoid arthritis, and multiple sclerosis.

In the highly competitive biopharmaceutical industry, BMS maintains a strong position, primarily due to its diverse portfolio of products and its ability to innovate and develop new treatments. Some of its key competitors include Pfizer, Johnson & Johnson, Merck, and AstraZeneca.

Although the text does not provide specific names of customers, it mentions that BMS's products are sold worldwide to various entities, including wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies.

Bristol-Myers Squibb Company's brand names and trade names of products and services, as mentioned in the text, include Eliquis, Opdivo, Orencia, Pomalyst, Imnovid, Yervoy, Sprycel, Reblozyl, Abecma, Opdualag, Breyanzi, Camzyos, Sotyktu, Onureg, Inrebic, and Zeposia.